Metazero

Metoprolol succinate, the active ingredient in Metazero, is a beta blocker presented as an oral tablet for oral use. It is used to lower high blood pressure, relieve chest pain from chronic stable angina, improve outcomes in heart failure, and reduce the risk of further events after a myocardial infarction in adult patients.

GNH USA supplies Metazero as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance.

Metazero (metoprolol succinate) is employed in cardiovascular therapy to control blood pressure and reduce cardiac workload.

Hypertension: reduces systolic and diastolic pressure, decreasing risk of stroke and heart attack. Chronic stable angina: decreases myocardial oxygen demand, relieving chest pain during exertion. Heart failure: improves left ventricular function and reduces hospitalization rates. Post‑myocardial infarction: lowers risk of recurrent infarction and improves survival.

Metazero may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed sensation, especially on standing. - Gastrointestinal upset: nausea, abdominal discomfort or constipation.

Serious or Rare Side Effects: - Severe hypotension: markedly low blood pressure causing fainting. - Bradycardia: dangerously slow heart rate. - Bronchospasm: narrowing of airways, particularly in patients with asthma.

When prescribing Metazero, clinicians should consider several precautionary measures to ensure safe use. - Assess cardiovascular status: evaluate heart rate, blood pressure and conduction abnormalities before initiation. - Review concomitant medications: avoid use with other β‑blockers or drugs that may exacerbate bradycardia. - Monitor renal and hepatic function: dose adjustments may be needed in impairment. - Caution in asthma or COPD: β1‑selectivity may still affect bronchial tone. - Pregnancy and lactation: use only if potential benefit justifies potential risk, as safety data are limited. - Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Metazero can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Non‑selective β‑blockers: combined use can cause excessive bradycardia and hypotension. - Calcium channel blockers (verapamil, diltiazem): increase risk of heart block and severe hypotension. - Antidiabetic agents (insulin, sulfonylureas): may mask hypoglycemia symptoms.

Moderate Interactions (Monitor Closely): - Antidepressants (SSRIs, SNRIs): may enhance bradycardic effects. - NSAIDs (ibuprofen, naproxen): can reduce antihypertensive effect. - Digoxin: may increase plasma levels leading to toxicity.